Correlates of parathyroid hormone concentration in hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 28, Issue 6, 2013, Pages 1516-1525

  Li, Jinnan ^a   Molnar, Miklos Z ^a,b,c   Zaritsky, Joshua J ^d   Sim, John J ^e   Streja, Elani ^a   Kovesdy, Csaba P ^f,g   Salusky, Isidro ^d   Kalantar Zadeh, Kamyar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hemodialysis; Serum alkaline phosphatase; Serum calcium; Serum intact parathyroid hormone; Serum phosphorous

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATASEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEGRO; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

HEMODIALYSIS; SERUM ALKALINE PHOSPHATASE; SERUM CALCIUM; SERUM INTACT PARATHYROID HORMONE; SERUM PHOSPHOROUS;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; CALCIUM; COHORT STUDIES; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROGNOSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84879852418     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs598     Document Type: Article

References (38)

1. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
2. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
3. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793
4. Lukowsky LR, Molnar MZ, Zaritsky JJ et al. Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2012; 27: 2899-2907
5. Shantouf R, Kovesdy CP, Kim Y et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1106-1114
6. Spiegel DM, Raggi P, Smits G et al. Factors associated with mortality in patients new to haemodialysis. Nephrol Dial Transplant 2007; 22: 3568-3572
7. Raggi P, Giachelli C, Bellasi A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nature clinical practice. Cardiovasc Med 2007; 4: 26-33
8. Shoji T, Maekawa K, Emoto M et al. Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis 2010; 210: 145-149
9. Kalantar-Zadeh K, Shah A, Duong U et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 2010; 117: S10-S21
10. Kovesdy CP, Ureche V, Lu JL et al. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010; 25: 3003-3011
11. Park JC, Kovesdy CP, Duong U et al. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int 2010; 14: 182-192
12. Molnar MZ, Kovesdy CP, Mucsi I et al. Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes. Clin J Am Soc Nephrol 2012; 7: 1859-1871
13. Kalantar-Zadeh K, Molnar MZ, Kovesdy CP et al. Management of mineral and bone disorder after kidney transplantation. Curr Opin Nephrol Hypertens 2012; 21: 389-403
14. Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130
16. Moore C, Yee J, Malluche H et al. Relationship between bone histology and markers of bone and mineral metabolism in African- American hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1484-1493
17. Kalantar-Zadeh K, Streja E, Kovesdy CP et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010; 85: 991-1001
18. Feroze U, Molnar MZ, Dukkipati R et al. Insights into nutritional and inflammatory aspects of low parathyroid hormone in dialysis patients. J Ren Nutr 2011; 21: 100-104
19. Molnar MZ, Streja E, Kovesdy CP et al. High platelet count as a link between renal cachexia and cardiovascular mortality in endstage renal disease patients. Am J Clin Nutr 2011; 94: 945-954
20. Ricks J, Molnar MZ, Kovesdy CP et al. Racial and ethnic differences in the association of body mass index and survival in maintenance hemodialysis patients. Am J Kidney Dis 2011; 58: 574-582
21. Streja E, Kovesdy CP, Molnar MZ et al. Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis 2011; 57: 883-893
22. Kalantar-Zadeh K, Streja E, Molnar MZ et al. Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis. Am J Epidemiol 2012; 175: 793-803
23. Ricks J, Molnar MZ, Kovesdy CP et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6- year cohort study. Diabetes 2012; 61: 708-715
24. Slatopolsky E, Caglar S, Pennell JP et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971; 50: 492-499
25. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
26. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
27. Kalantar-Zadeh K, Miller JE, Kovesdy CP et al. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res 2010; 25: 2724-2734
28. Noordzij M, Korevaar JC, Boeschoten EW et al. The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932
29. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127
30. Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol 1999; 277: F665-F675
31. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342
32. Qi Q, Monier-Faugere MC, Geng Z et al. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631
33. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203
34. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl. 3): S1
35. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992; 38: S62-S67
36. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861
37. Miller JE, Kovesdy CP, Norris KC et al. Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol 2010; 32: 403-413
38. Block GA. Therapeutic interventions for chronic kidney diseasemineral and bone disorders: focus on mortality. Curr Opin Nephrol Hypertens 2011; 20: 376-381